Literature DB >> 27073449

Effects of simvastatin and taurine on delayed cerebral vasospasm following subarachnoid hemorrhage in rabbits.

Cheng Lin1, Yuanli Zhao2, Gang Wan3, Anlin Zhu3, Hao Wang2.   

Abstract

The aim of the current study was to observe the effects of simvastatin and taurine on delayed cerebral vasospasm (DCVS) following experimental subarachnoid hemorrhage (SAH) in rabbits. A total of 48 New Zealand white rabbits were allocated at random into four groups (control, SAH, SAH + simvastatin and SAH + taurine groups; n=12 each). The rabbit model of DCVS was established using a double hemorrhage method, which involved injecting autologous arterial blood into the cisterna magna in the SAH groups. The SAH + simvastatin group was administered oral simvastatin (5 mg/kg) daily between days 0-6. The SAH + taurine group was administered oral taurine (50 mg/kg) daily between days 0-6. Starch (50 mg/kg) was administered orally to the animals in the other two groups (control and SAH groups). The control group were not subjected to any other injections or treatment. The internal diameter and internal diameter/wall thickness of the basilar artery (BA) were measured. The expression levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 were determined using immunohistochemical and quantitative polymerase chain reaction methods following the sacrifice of all animals on day 7. The activity of nuclear factor (NF)-κB in the BA was also measured using an electrophoretic mobility shift assay. The BA walls in the SAH + simvastatin and SAH + taurine groups exhibited reduced narrowing and corrugation of the tunica elastica interna compared with the SAH group. At the protein and cDNA levels, it was found that cerebral vasospasm of the BA in the SAH + simvastatin and SAH + taurine groups was alleviated, as indicated by the reduced expression of TNF-α, IL-1β, IL-6 and NF-κB compared with the SAH group (P<0.05). In conclusion, simvastatin and taurine reduced DCVS following SAH in rabbits, which suggests that these compounds may exert anti-inflammatory effects.

Entities:  

Keywords:  cerebral vasospasm; inflammation; simvastatin; subarachnoid hemorrhage; taurine

Year:  2016        PMID: 27073449      PMCID: PMC4812265          DOI: 10.3892/etm.2016.3082

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  43 in total

1.  Tenascin-C is a possible mediator between initial brain injury and vasospasm-related and -unrelated delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Authors:  Hidenori Suzuki; Kenji Kanamaru; Masato Shiba; Masashi Fujimoto; Fumio Kawakita; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; Waro Taki
Journal:  Acta Neurochir Suppl       Date:  2015

2.  Nonsteroidal anti-inflammatory drugs as risk factors for spontaneous intracerebral hemorrhage and aneurysmal subarachnoid hemorrhage.

Authors:  Seppo Juvela
Journal:  Stroke       Date:  2003-05-15       Impact factor: 7.914

3.  Taurine chloramine inhibits production of inflammatory mediators and iNOS gene expression in alveolar macrophages; a tale of two pathways: part I, NF-kappaB signaling.

Authors:  Michael R Quinn; Madhabi Barua; Yong Liu; Valeria Serban
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

4.  Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.

Authors:  Minoru Asahi; Zhihong Huang; Sunu Thomas; Shin-ichi Yoshimura; Toshihisa Sumii; Tatsuro Mori; Jianhua Qiu; Sepideh Amin-Hanjani; Paul L Huang; James K Liao; Eng H Lo; Michael A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  2005-06       Impact factor: 6.200

5.  Anti-inflammatory effects of simvastatin in patients with chronic heart failure.

Authors:  T V Pinchuk; Yu N Fedulaev; G A Khairetdinova; N N Denisova; O V Chura; I Yu Logunova
Journal:  Bull Exp Biol Med       Date:  2014-09-27       Impact factor: 0.804

6.  Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm.

Authors:  Chih-Lung Lin; Aaron S Dumont; Tarkan Calisaneller; Aij-Lie Kwan; Shen-Long Hwong; Kevin S Lee
Journal:  Surg Neurol       Date:  2005-09

Review 7.  Roles of signal transduction mechanisms in cerebral vasospasm following subarachnoid hemorrhage: overview.

Authors:  Shigeru Nishziawa
Journal:  Acta Neurochir Suppl       Date:  2011

Review 8.  Statins: a potential therapeutic addition to treatment for aneurysmal subarachnoid hemorrhage?

Authors:  Mohammed Sabri; R Loch Macdonald
Journal:  World Neurosurg       Date:  2010-06       Impact factor: 2.104

9.  Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB.

Authors:  Ming Sun; Yumei Zhao; Yi Gu; Chao Xu
Journal:  Amino Acids       Date:  2011-03-16       Impact factor: 3.520

10.  Severe reversible cerebral vasoconstriction syndrome mimicking aneurysmal rupture and vasospasm.

Authors:  Christopher Nickele; Kenji Muro; Christopher C Getch; Matthew T Walker; Richard A Bernstein
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

View more
  3 in total

Review 1.  Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy?

Authors:  Davide Marco Croci; Sivani Sivanrupan; Stefan Wanderer; Guilherme J Agnoletto; Alessio Chiappini; Basil E Grüter; Lukas Andereggen; Luigi Mariani; Philipp Taussky; Serge Marbacher
Journal:  Neurosurg Rev       Date:  2021-08-27       Impact factor: 2.800

2.  Simvastatin improves intracerebral hemorrhage through NF-κB-mediated apoptosis via the MyD88/TRIF signaling pathway.

Authors:  Chengyao Gu; Yunqin Wu; Zhenyi Fan; Weiwei Han
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

3.  Anti-inflammatory effects of Simvastatin in patients with acute intracerebral hemorrhage in an intensive care unit.

Authors:  Xiurong Zhou; Jiafeng Chen; Chengdong Wang; Lili Wu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.